Federal regulators have approved Eli Lillys new weight-loss pill, orforglipron, branded as Foundayo. Its the second daily oral option for obesity and related issues, working like popular injections by mimicking a hormone that curbs hunger and boosts fullness. The pill is set to hit the market fast, with shipments starting Monday. Folks with insurance could snag it for as low as twenty-five dollars a month using a Lilly discount card, while cash payers face one hundred forty-nine to three hundred forty-nine dollars depending on the dose. It joins Novo Nordisks oral Wegovy, which has racked up over six hundred thousand prescriptions in the US since its December approval. The FDA sped through approval in just fifty days under a new fast-track program. Unlike Wegovy, which needs an empty stomach and a thirty-minute wait after a sip of water, orforglipron has no such hassle since its a small-molecule drug. Studies showed users dropping waist size, blood pressure, triglycerides, and cholesterol, though five to ten percent quit due to gut issues like nausea, compared to three percent on placebo. Plus, its part of a deal to slash prices on these GLP-one drugs moving forward.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/f80f01efaafa718d

Amazon Eyes Satellite Market, Negotiates Globalstar Buyout

China's Quantum Leap: A Threat to U.S. Secrets?